Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated Pleated Office (DO) Construing a Submission United States Designated Pleated Office (DO) Construing a Submission United States Designated Pleated Office (DO) Construing a Submission United States Designated Pleated Office (DO) Construing a Submission United States Designated Pleated Office (DO) Construing a Submission United States Designated Pleated Office (DO) Construing a Submission United States Designated Pleated Office (DO) Construing a Submission United States Designated Pleated Office (DO) Construing a Submission United States Designated Pleated Office (DO) Construing a Submission United States Designated Pleated Office (DO) Construing a Submission United States Designated Pleated Office (DO) Construing a Submission United States Designated Pleated Office (DO) Construing a Submission United States Designated Pleated Office (DO) Construing a Submission United States (DO) Construing a Submission United States (DO) Construing a Submission (DO) Constr	£35 2.6666i"					
U. S. PATENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE 21613P	ATTORNEY'S DOCKET NUMBER					
TDANSMITTAL LETTED TO THE UNITED STATES	- 27 CED 1.6)					
DESIGNATED/ELECTED OFFICE (DO/EO/US)  U.S. APPLICATION NO. (If known, s	•					
CONCERNING A FILING UNDER 35 U.S.C. 371 10/586 97	<u> </u>					
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PCT/US2005/001344 18 January 2005 PRIORITY DATE CLAIMED 20 January 2004						
TITLE OF INVENTION	_					
ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES						
APPLICANT(S) FOR DO/EO/US	****					
Guo Q. Shi, Peter T. Meinke, James F. Dropinski, Yong Zhang						
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:						
1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.						
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.						
3. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.						
4. X The US has been elected (PCT Article 31).						
5. A copy of the International Application as filed [35 U.S.C. 371(c)(2)]						
a is attached hereto (required only if not communicated by the International Bureau).						
b.  has been communicated by the International Bureau.						
c. X is not required, as the application was filed in the United States Receiving Office (RO/US).						
6. An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)].  a. is attached hereto						
b. has been previously submitted under 35 U.S.C. 154(d)(4).						
7. Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)].  a. are attached hereto (required only if not communicated by the International Bureau).						
b. have been communicated by the International Bureau.						
c. have not been made; however, the time limit for making such amendments has NOT expired.						
d. X have not been made and will not be made.						
8. An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 3710]	c)(3)].					
9. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].						
10. An English language translation of the annexes of the International Preliminary Examination Report und Article 36 [35 U.S.C. 371(c)(5)].	ler PCT					
Items 11 to 20 below concern other document(s) or information included:  11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.	31					
is included.						
13. X A preliminary amendment.						
14. An Application Data Sheet under 37 CFR 1.76.  15. A substitute specification.						
<ul> <li>16.  A power of attorney and/or change of address letter.</li> <li>17.  A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.</li> </ul>						
18. A second copy of the published International Application under 35 U.S.C.154(d)(4).						
19. A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).						
	ソく・ア					

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated Recent Direct DO/ED/US) Concerning a Submission Under 35 U.S.C. 371"

Approved for use through 3/31/2007. OMB 0651-0021

U.S. APPLICATION N	O. (If known, see 37 C	THE INTERI	NATIONAL APPLICATION NO	Э.		ATTORNEY'S DOC	CKET NUMBER
U.S. APPLICATION N	0/586	9 / O PCT/U	S2005/001344			21613P	
	fees are submitted:					CALCULATIONS	PTO USE ONLY
21. X Basic nat	tional fee	••••••			\$300	\$300.00	
<b> </b>	tion fee (37 CFR 1.4						
			preliminary examination rep		<b>€</b> ∩		
	prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)					\$200.00	
23. X Search fee	(37 CFR 1.492(b))	)				4300.00	
			ninary examination report pr				
g.			e 33(1)-(4) ional application to the USP				
International Searchin	ng Authority	***************************************				\$400.00	
previously communic	Report prepared by a ated to the US by the	an ISA other than the	US and provided to the Offi	се ог	\$400	·	
			•••••				
			TOTAL O			\$900.00	
	am listing filed in ar		per over 100 sheets (excluding . The fee is \$250 for each according to the second sec				
Total Sheets	Extra Sheets		additional 50 or fraction p to a whole number)		RATE		
49 - 100 =	0 /50	0 =	•	x	\$250.00	\$0.00	
Surcharge of \$130.0	0 for furnishing the	oath or declaration la	ater than 30 months from the	earlies	t claimed		
priority date [37 CF]	R 1.492(e)].			1			<u></u>
CLAIMS	NUMBE	R FILED	NUMBER EXTRA	<b>.</b>	RATE		,
Total Claims		17 - 20 =	0	X	\$50.00	\$0.00	
Independent Claims		1 -3=	0	X	\$200.00	\$0.00	
MULTIPLE DEPENI	DENT CLAIM(S) (i	f applicable)		+	\$360.00		
	TOTAL O	F ABOVE CALCU	LATIONS (SUBTOTAL)		=	\$900.00	
Processing fee of \$130 claimed priority date (	_	he English translatio	n later than 30 months from	the earl	iest +		
			TOTAL NATIONA	L FEE	=	\$900.00	
_			The assignment must be 31).\$40.00 per property.		+		
			TOTAL FEES ENCL	OSED	=	\$900.00	
	· · · · · ·					Amount to be	
•						refunded:	
						Amount to be charged:	
a. A check	k in the amount o	f \$	to cover the above fees	is encl	osed.	,	<u>,,</u>
b. 🔀 Please	charge my Depos		2755 in the amount of \$			cover the above fees.	
c. The Co	mmissioner is her	eby authorized to	charge any additional fees 3-2755. A duplicate copy				
			CFR 1.494 or 1.495 has tional Application to pe			ition to revive [37 CF	R 1.137(a) or
SEND ALL CO	RRESPONDENC	E TO:					
Customer No	. 000210		0				
MERCK & CO.,	INC		Ţ.	\	\	2	
Patent Department, RY60-30							
P.O. Box 2000	Avenue		S	IQNA	TURE		
126 East Lincoln Rahway, New Je	n Avenue rsey 07065-0970	1		U	<u></u>		
	,		_	mes L	. McGinnis		
DATE: July 19.	2006		Ŋ	(AIVI C			
PHONE #: (732) 594-0641 34,387  REGISTRATION NUMBER					DADED		
1			R	COIN	IKAHON NI	INBEK	

## 10/586976 IAP6 Rec'd PCT/PTO 19 JUL 2006

## Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Attorney Docket 110	21015
International Appln No.:	PCT/US2005/001344
International Filing Date:	18 January 2005
Priority Date:	20 January 2004
Title:	ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES
Inventors:	Guo Q. Shi, Peter T. Meinke, James F. Dropinski, Yong Zhang

21613

Attorney Docket No.

**EXPRESS MAIL CERTIFICATE** EXPRESS MAIL NO. EV 660608903 US I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450. Klittlowski DATE 7-19-06

Computer generated form "TransLetter (DO-EO-US)" (PCT Folder), Merck & Co., Inc., 12/2/2005